Teva Pharmaceutical Cash Flow - Quarterly (NYSE:TEVA)

Add to My Stocks
$24.83 $0.19 (0.77%) TEVA stock closing price Sep 20, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Teva Pharmaceutical needs to disclose. The profit-loss statement shows Teva Pharmaceutical profits, the balance sheet shows Teva Pharmaceutical debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Teva Pharmaceutical stock analysis. Teva Pharmaceutical had a positive net income cash flow of $968M till this quarter of 2018 Q2. This report is very useful in measuring the short term viability of a company. The cash from operating activities for Teva Pharmaceutical is $ 2018 Q2, which saw an increase from previous quarter.

View and download details of Teva Pharmaceutical cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
968M1.13B-16.45B-4.72B-5.33B641M311M1.29B875M633M
Depreciation Depletion Amortization Cash-Flow986M507M2.11B1.58B1.06B480M1.52B1.19B615M305M
Net Increase (Decrease) in Assets Liabilities-1.27B-592M-363M-755M-711M-463M1.22B1.1B53M189M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net972M447M18.21B6.22B6.19B-188M2.17B223M796M249M
Net Cash from (used by) Operating Activities
1.66B1.5B3.51B2.33B1.21B470M5.23B3.8B2.34B1.38B
Increase (Decrease) in Prop Plant And Equipment542M661M2.6B1B1.09B1.21B1.1B1.23B-308M-170M
Acquisition Disposition of Subsidiaires--43M43M---36.15B-35.87B-2.31B-2.24B
Increase (Decrease) in Investments-56M-56M-200M-194M-14M-6M-481M-316M-37M-29M
Other Cash Inflow (Outflow) from Investment Activities959M434M-282M-277M-286M-22M-212M15M15M18M
Net Cash from (used by) Investment Activities
1.45B1.04B2.16B572M790M1.18B-35.74B-34.94B-2.64B-2.42B
Issuance (Purchase) of Equity Shares------364M363M349M342M
Issuance (Repayment) of Debt Securities-1.85B-1.8B-2.79B-498M-62M-24.58B25.53B284M285M
Increase (Decrease) in Bank & Other Borrowings-261M-261M-1.68B-1.63B-1.48B-1.35B2B1.32B758M38M
Payment of Dividends & Other Cash Distributions-22M-22M-1.16B-1.01B-821M-411M-1.56B-1.15B-743M-367M
Other Cash from (used by) Financing Activities-10M-5M-112M-107M-59M-7M-169M-143M-102M-31M
Net Cash from (used by) Financing Activities
-2.15B-2.09B-5.75B-3.24B-2.42B-1.77B25.22B25.92B546M267M
Effect of Exchange Rate Changes on Cash-58M11M54M36M29M28M-660M-164M-205M-208M
Net Change in Cash & Cash Equivalents
898M455M-25M-308M-389M-88M-5.96B-5.39B38M-982M
Cash & Equivalents at Beginning of Year963M988M6.95B2.23B1.04B2.88B1.1B1.25B2B1.85B
Cash & Equivalents at Year End1.86B1.42B963M680M599M900M988M1.56B6.98B5.96B
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Teva Pharmaceutical stock price history provides insight into historical stock price fluctuations, and Teva Pharmaceutical stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Teva Pharmaceutical saw a positive change in Net Change in Cash and Cash Equivalents of $898M till 2018 Q2. Apart from the Teva Pharmaceutical stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Teva Pharmaceutical increased its cash from operating activities to $1.66B till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $1.45B for TEVA till last quarter 2018 Q2 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-2.15B for Teva Pharmaceutical. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Teva Pharmaceutical Cash Flow

FCF margin
0.01

Quarterly Cash Flow Statements For Teva Pharmaceutical Industries Ltd (ADR) Peers

Allergan cash flow, Astrazeneca cash flow, Eagle Pharma cash flow, Fortress Biotech cash flow, Mylan cash flow